Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) shares were up 1.4% during trading on Monday. The stock traded as high as $66.55 and last traded at $64.51. 684,730 shares changed hands during trading, an increase of 262% from the average session volume of 189,291 shares. The stock had previously closed at $63.61.
Gemini Therapeutics Trading Down 2.7%
The firm’s 50 day simple moving average is $74.76 and its 200-day simple moving average is $71.24. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of -61.65 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc was a clinical-stage biotechnology company focused on developing precision medicines for genetically defined diseases. Its research centered on the complement system, an area of the immune system implicated in several ophthalmic and inflammatory conditions.
The company’s lead product candidate was GEM103, a recombinant form of complement factor H being investigated as a potential treatment for geographic atrophy, an advanced form of dry age-related macular degeneration.
Further Reading
- Five stocks we like better than Gemini Therapeutics
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
- Morgan Stanley Is Bullish on Apple—But With a Catch
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
